Mark G. Foletta Sells 2,750 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director now owns 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $0.82 during trading on Wednesday, hitting $81.01. The company had a trading volume of 4,738,212 shares, compared to its average volume of 4,345,532. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.49. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market capitalization of $31.76 billion, a P/E ratio of 60.46, a price-to-earnings-growth ratio of 1.77 and a beta of 1.46. The stock has a 50 day simple moving average of $79.25 and a 200 day simple moving average of $79.38.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 earnings per share. As a group, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently bought and sold shares of the business. Proficio Capital Partners LLC bought a new stake in DexCom during the 4th quarter valued at approximately $5,812,000. SBI Securities Co. Ltd. purchased a new stake in DexCom during the 4th quarter valued at approximately $49,000. Van ECK Associates Corp grew its holdings in DexCom by 325.0% during the 4th quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company's stock valued at $6,674,000 after buying an additional 65,622 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of DexCom by 28.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company's stock valued at $4,596,000 after buying an additional 13,111 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its position in shares of DexCom by 45.5% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 55,752 shares of the medical device company's stock worth $4,336,000 after acquiring an additional 17,435 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DXCM shares. Piper Sandler decreased their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Barclays raised their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Truist Financial initiated coverage on DexCom in a research report on Monday. They issued a "buy" rating and a $102.00 target price for the company. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.